PCVX – vaxcyte, inc. (US:NASDAQ)
Stock Stats
News
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults [Yahoo! Finance]
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte (PCVX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]
Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: VANGUARD GROUP INC
Form 4 Vaxcyte, Inc. For: Mar 17 Filed by: Cowan Elvia
Form 144 Vaxcyte, Inc. Filed by: Cowan Elvia
Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: Dhaliwal Harpreet S.
Form 4 Vaxcyte, Inc. For: Mar 09 Filed by: GUGGENHIME ANDREW
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.